血栓出血性の英語

その結果、従来の脳血管障害の危険因子に加え、アテローム血栓性脳梗塞では８個の遺伝子多型、脳出血では９個の遺伝子多型、クモ膜下出血では１０個の遺伝子多型を加えたリスク検出法は、脳血管障害の一次、二次予防に有用であることが示された。例文帳に追加

As a result of the investigation, it has been clarified that the risk detection based on 8 genetic polymorphisms for atherothrombotic cerebral infarction, 9 genetic polymorphisms for cerebral hemorrhage and 10 genetic polymorphisms for subarachnoid hemorrhage in addition to the conventional risk factors for cerebrovascular disorder is useful for the primary and secondary prevention of cerebrovascular disorder. - 特許庁

経口投与可能で活性化血液凝固第Ｘ因子を良好かつ選択的に阻害する、出血リスクの少ない血液凝固、血栓、塞栓に起因する疾病の治療に有用な化合物及び該化合物を含む医薬組成物を提供すること。例文帳に追加

To provide a compound which is available in oral administration, favorably and selectively inhibits activated blood coagulation factor X, and is useful in treating diseases caused by blood coagulation, thrombus and embolus with little hemorrhage risk, and a medicinal composition containing the compound. - 特許庁

１１４１人の脳血管障害患者（アテローム血栓性脳梗塞患者６３６人、脳出血患者２８２人、クモ膜下出血患者２２３人）とコントロール者２０１０人とについて、１５２個の候補遺伝子に関し２０２個の遺伝子多型を測定し、上記３疾患の発症に有意に関連する遺伝子多型を検出した。例文帳に追加

Two hundred and two genetic polymorphisms relating to 152 candidate genes were measured on 1,141 patients of cerebrovascular disorder (636 patients of atherothrombotic cerebral infarction, 282 patients of cerebral hemorrhage and 223 patients of subarachnoid hemorrhage) and 2,010 controls to detect genetic polymorphisms significantly relating to the onset of these 3 diseases. - 特許庁